NRx Pharmaceuticals, Inc.
NRXP
$2.24
-$0.0539-2.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.51M | 12.78M | 12.86M | 12.68M | 14.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.70M | 20.48M | 23.26M | 24.15M | 27.59M |
| Operating Income | -19.70M | -20.48M | -23.26M | -24.15M | -27.59M |
| Income Before Tax | -25.13M | -20.38M | -24.82M | -25.64M | -30.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.13 | -20.38 | -24.82 | -25.64 | -30.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.13M | -20.38M | -24.82M | -25.64M | -30.15M |
| EBIT | -19.70M | -20.48M | -23.26M | -24.15M | -27.59M |
| EBITDA | -19.70M | -20.47M | -23.26M | -24.15M | -27.58M |
| EPS Basic | -2.38 | -2.17 | -2.77 | -3.21 | -4.13 |
| Normalized Basic EPS | -1.41 | -1.42 | -1.68 | -1.88 | -2.31 |
| EPS Diluted | -2.38 | -2.17 | -2.77 | -3.23 | -4.15 |
| Normalized Diluted EPS | -1.41 | -1.42 | -1.68 | -1.88 | -2.31 |
| Average Basic Shares Outstanding | 42.59M | 38.41M | 35.64M | 32.44M | 30.23M |
| Average Diluted Shares Outstanding | 42.59M | 38.41M | 35.64M | 32.44M | 30.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |